Comparison of the CytoSorb® 300 mL and Jafron HA380 hemoadsorption devices: an in vitro study. Issue 7 (3rd October 2022)

• Record Type: Journal Article
• Authors: Nierhaus, Axel; Morales, Jesus; Wendt, Daniel; Scheier, Jörg; Gutzler, Dominik; Jarczak, Dominik; Born, Frank; Hagl, Christian; Deliargyris, Efthymios; Mehta, Yatin
• Is Part Of: Minimally invasive therapy & allied technologies. Volume 31:Issue 7(2022)
• Page Start: 1058
• Page End: 1065
• Publication Date: 2022-10-03
• Subjects: Hemoadsorption -- porous polymer beads -- blood purification -- sepsis -- cytokines; Endoscopy -- Periodicals; Interventional radiology -- Periodicals; Endoscopic surgery -- Periodicals; 617.05
• DOI: 10.1080/13645706.2022.2104617
• Languages: English
• ISSNs: 1364-5706

Abstract

Abstract: Introduction: We performed an analysis of two blood purification systems to determine their performance for removing interleukins (ILs)-6 and 10, tumor necrosis factor (TNF)-α and monocyte chemoattractant protein (MCP)-1 from blood. Material and methods: An in vitro hemoperfusion blood recirculation circuit was used to compare the CytoSorb ® 300 mL (CytoSorbents Inc., Princeton, NJ) and Jafron HA 380 (Jafron Biomedical Co., Ltd., Zhuhai City, China) devices. The removal of purified recombinant human IL-6, IL-10, TNFα and MCP-1 by the adsorbers was compared at various timepoints. Three runs were completed and removal was evaluated as the mean area under the curve (AUC). Results: Both devices showed effective removal of the tested cytokines. IL-6, IL-10, TNFα and MCP-1 were removed faster and to a higher extent by the CytoSorb ® 300 mL device. At maximal time of 12 h, overall removal according to AUC of remaining concentrations was significantly lower with CytoSorb ® 300 mL compared with HA 380 (IL-6: 1075.5 ± 665.9 vs. 4345.1 ± 1499.3 ( p = 0.01), IL-10: 5065.7 ± 882.5 vs. 11, 939.7 ± 4523.1 ( p = 0.03), TNF-α: 6519.9 ± 997.6 vs. 10, 303.7 ± 2347.0 ( p = 0.03) and MCP-1: 278.9 ± 40.7 vs. 607.3 ± 84.4 ( p = 0.001)). Conclusions: Both the CytoSorb ® and the Jafron HA 380 devices are capable of removing cytokines from blood in a benchtop model. The CytoSorb ® 300 device was significantly more efficient achieving the bulk of the removal in the first 120 min.